David Weingard, chief impact officer of T1D Moonshot and founder of Cecelia Health, tells us how T1D Moonshot aims to break silos and advance type 1 diabetes prevention and treatment option
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.